Background: The mechanisms of multiple sclerosis (MS) pathogenesis are still largely unknown. The heterogeneity of disease manifestations make the prediction of prognosis and choice of appropriate treatment protocols challenging. Recently, increased cerebrospinal fluid (CSF) levels of the B-cell chemokine CXCL13 was proposed as a possible marker for a more severe disease course and conversion from clinically isolated syndrome (CIS) to relapsing-remitting MS (RRMS). Objective: To investigate whether there are genetic susceptibility variants in MS that correlate with the levels of CXCL13 present in the CSF of MS patients. Methods: We genotyped the human leukocyte antigens HLA-DRB1 and HLA-A, plus a panel of single nucleotide polymorphisms (SNPs) that have been associated with susceptibility to MS and then correlated the genotypes with the levels of CXCL13, as measured with ELISA in the CSF of a total of 663 patients with MS, CIS, other neurological diseases (OND) or OND with an inflammatory component (iOND). Results: Presence of the HLA-DRB1*15 and the MS risk genotypes for SNPs in the RGS1, IRF5 and OLIG3/TNFAIP3 gene regions correlated significantly with increased levels of CXCL13. Conclusion: Our results pointed towards a genetic predisposition for increased CXCL13 levels, which in MS patients correlates with the severity of the disease course. These findings encourage further investigation and replication, in an independent patient cohort.
Introduction
The etiology of multiple sclerosis (MS) is multifactorial, where both genes and environmental factors affect susceptibility. The strongest genetic association is to the human leukocyte antigen (HLA) locus, but several non-HLA risk genes were also recently confirmed. 1 Due to its complex etiology, the mechanisms of pathogenesis for MS are still largely unknown: the heterogeneity of disease phenotypes makes the investigation of pathogenesis challenging. In the context of treatment, only patients with relapsing-remitting MS (RRMS) are currently suitable for receipt of diseasemodifying drugs; however, even within this group, large differences exist in disease activity and in the patient's response to different treatments. This highlights the need for identification of reliable and validated prognostic biomarkers that can help predict disease prognosis and enable provision of appropriate treatment protocols.
CXCL13 is a selective chemoattractant of B cells that functions via its receptor, CXCR5. It is known that the CXCL13 chemokine is expressed in active MS lesions, 2 it is upregulated in the CSF of MS patients, and that it correlates with the number of B cells present in the CSF of patients with clinically isolated syndrome (CIS) and RRMS. 2, 3 Although it is not specific to MS and high CSF levels can be found in other infections and inflammatory conditions in the central nervous system (CNS), 4, 5 CXCL13 recently emerged as a suggested prognostic marker for MS. It is found to be significantly elevated in CSF, among CIS patients who later converted to RRMS, as compared to those who did not convert and to the study controls. 6, 7 In addition, high concentrations of CXCL13 are positively correlated with increased MS disease activity (a high 5-year relapse rate, high Expanded Disability Status Scale (EDSS) score, more MRI lesions and the presence of oligoclonal immunoglobulin (Ig) bands (OCB) in patients, deemed OCB+ CIS or MS). 7 The role of B cells in MS pathogenesis and progression is not yet defined; however, several observations support the notion that B-cell immunology is of importance. Thus, OCBs are present in the CSF of a majority of MS patients and their B-cell responses are more pronounced in acute CNS inflammation, which can be observed in both CIS and RRMS. Moreover, recent phase II trials using B-cell depleting antibodies show a striking decrease of gadolinium (Gd)-enhancing lesions in relapsing-remitting patients. 8,9 B cells will migrate to the CNS via the blood-brain barrier, as a response to a chemotactic gradient of chemokines, of which CXCL13 has one of the most potent effects.
So far, non-HLA MS risk genes have not been demonstrated to provide any influence on the severity of the disease course, while this is common for genes that are mapped in the experimental models for MS, experimental autoimmune encephalomyelitis. 10, 11 This could in principle be due to the following reasons: Either the genes detected so far only regulate incidence, and not disease course; because severity-related genes are different and thus not found by the current ways used to decipher the genetics of MS; or the ways that we assess severity today are too blunt or insensitive to allow discernment of geno-phenotype correlations. An alternative way to assess these matters would be to relate MS risk genes to sub-phenotypes, such as searching for biomarkers that predict severity and/or disease course in these subsets.
In this study, we have investigated whether there are genetic susceptibility variants that predispose to elevated levels of CXCL13 and thus, reinforce the search for a possible set of markers that could be used for prediction of prognosis, at the level of the individual patient. Moreover, we believe that combining genotypic and phenotypic data from patients might provide useful information about possible disease mechanisms. To this end, we investigated a panel of polymorphisms in established MS susceptibility loci, as well as a few single nucleotide polymorphisms (SNPs) that show an association with MS in some populations, and we then analyzed their relationships with the levels of CXCL13 found in CSF.
Subjects, materials and methods

Patients
We included 663 subjects in this study. The MS patients fulfilling the McDonald criteria 11 consisted of those having RRMS (n = 266), SPMS (n = 35) and PPMS (n = 19). The CIS group consisted of 90 subjects. Our control cohort consisted of 116 individuals with other neurological diseases (ONDs) such as migraine, psychosis, vertigo; and 137 individuals with inflammatory OND (iOND) who had diagnoses such as post-polio syndrome and systemic lupus erythematosus (SLE). As it was previously reported that patients with viral or bacterial infections, such as herpes encephalitis or neuroborreliosis, have extremely high CXCL13 levels in the CSF, 7 we excluded them from our study. All our subjects were part of the cohort used to study CSF levels of CXCL13 in relation to MS diagnosis and prognosis, so they are described in more detail elsewhere. 7 
CSF, DNA and RNA samples
The CSF and blood samples were collected during routine neurological diagnostic work-ups. We collected peripheral blood in sodium citrate-containing cell preparation tubes (Vacutainer CPT; BD Biosciences, San Jose, California, USA) and EDTA tubes. The peripheral blood mononuclear cells (PBMCs) were separated by density gradient centrifugation: cells from the interphase were collected and washed twice with Dulbeccos's phosphate buffered saline (PBS). The PBMC pellets were stored at −80 o C.
CSF samples were centrifuged immediately after sampling, to isolate cells and larger particles. Both cell pellets and cell-free CSF were stored frozen at −80 o C, until analysis. We extracted DNA from EDTA-treated blood using a QIAamp DNA Blood Maxi Kit and we extracted total RNA from the CSF cell pellets and PBMCs, using a RNeasy Mini Kit, according to the manufacturer's protocol (Qiagen, Hilden, Germany). All samples were stored in our in-house biobank, prior to analysis.
The study was approved by the regional ethics committee. Written informed consent was obtained from all patients.
ELISA measurements
We measured CXCL13 levels using commercially available enzyme-linked immunosorbent assay (ELISA) kits (Quantikine; Human CXCL13/BLC/BCA-1; R&D Systems, Abingdon, UK), according to the manufacturer's instructions. Measurements were performed in duplicate, using 50 µl of undiluted cell-free CSF.
Genotyping
For the HLA-DR and HLA-A typing, we carried out sequence-specific amplification using Olerup SSP ® low-resolution kits 12 (Olerup SSP AB, Stockholm, Sweden). HLA-DRB1 and HLA-A were typed for all currently known alleles at low resolution (i.e. two digits). Allelic discrimination of SNPs was performed with matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (Sequenom Inc., San Diego, California, USA), as described previously; 13 or TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City, California, USA), according to the manufacturer's protocol, and using the 7900HT Fast Real-Time PCR System for PCR amplification. We used SDS 2.4 software for allelic discrimination.
Bioinformatic analysis
A scan for reported expression quantitative trait loci (eQTLs) for CXCL13 was performed using the following databases: SCAN, 13 the eQTL Browser (http://eqtl.uchicago.edu/ Home.html), PheGenI (http://www.ncbi.nlm.nih.gov/gap/ PheGenI?tab=1&gene=10563) and seeQTL database. 14 
Gene expression analysis
Our cDNA synthesis was performed using the iScript Reverse Transcription Kit (BioRad Laboratories, Hercules, California, USA), according to the manufacturer's protocol. Quantitative real-time PCR was run on a BioRad iQ5 iCycler Detection System and we used SYBR-Green-based primers (sequences available upon request). For TNF and IFN-γ, we performed the relative quantification of mRNA concentrations using the standard curve method, with amplification of target mRNA and GAPDH mRNA. We calculated the relative amount of mRNA in each sample as the ratio between the target mRNA and the corresponding endogenous control GAPDH mRNA. For quantification of IL6 expression, the 2 -ΔΔCT formula was used, where the amount of target gene was first normalized to GAPDH.
Statistical methods
Because CXCL13 levels were normally distributed in our cohort, we decided to use parametric methods for the statistical analysis. We used PLINK v.1.07 software 15 (http:// pngu.mgh.harvard.edu/purcell/plink/) to perform the Wald test for quantitative trait association. The statistical testing was performed in three sets: Set 1 included all individuals; Set 2 included individuals with OND and iOND; and Set 3 included only individuals with MS and CIS. P-values adjusted for multiple testing were computed using Benjamini-Hochberg (BH) corrections. 16 Differences in CXCL13 levels between different diagnosis groups were tested using a one-way analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons. We analyzed differences in CXCL13 levels between the different genotype groups using the student's t-test, with Welch's correction for unequal variances when applicable (GraphPad Prism 5.0; GraphPad Software, Inc., San Diego, California, USA).
Results
In all the subjects that were genotyped, the concentration of CXCL13 in CSF was also measured. Our study subjects were a part of a larger cohort showing an association of increased CXCL13 levels with MS. 7 We confirmed that levels of the chemokine measured in our current subset of subjects were significantly higher in MS patients, as compared to OND and iOND controls ( Figure 1 ).
The following markers that we genotyped are located in regions that are established as associated with MS: HLA-DRB1*15, HLA-A*02, rs10735781 (EVI5), rs2760524 (RGS1), rs4680534 (IL12A), rs6897932 (IL7R), rs9321619 (OLIG3/TNFAIP3), rs2104286 (IL2RA), rs17824933 (CD6), rs1800693 (TNFRSF1A), rs12708716 (CLEC16A), rs6498169 (CLEC16A), rs17445836 (IRF8), rs744166 (STAT3), rs763361 (CD226), rs34536443 (TYK2). 1 In addition, we typed some markers that had been either associated with MS in some populations or were located in regions having weaker evidence of an association: rs4728142 (IRF5), 17 rs3807306 (IRF5) 17 (also Izaura Lima Bomfim et al., unpublished results), rs11594656 (RBM17), 18 rs3184504 (SH2B3), 19 rs34925346 (RGMA), 20 rs8060368 (IL21R), 20 rs2546133 (VAV1), 21 rs2617822 (VAV1) 21 and rs2304256 (TYK2). Table  1 lists all markers and the number of individuals typed for each marker. Set 1 included all individuals, Set 2 OND and iOND, and Set 3 included only individuals with MS or CIS. The Wald test was performed in order to assess the correlation of the quantitative trait CXCL13 with the markers. After adjustment for multiple testing, we found that the HLA-DRB1*15, rs9321619 (OLIG3/TNFAIP3), rs4728142 (IRF5), rs3807306 (IRF5) and rs34925346 (RGMA) genotypes remained significantly correlated with the mean CXCL13 levels obtained in the CSF of Set 1 and Set 3. We found that rs2760524 (RGS1) was significant only in Set 1 ( Table 1) . The genotype frequencies and mean levels of CXCL13 per genotype can be found in Supplementary Table 1 .
The Wald test provides information on whether there is any difference in the quantitative trait levels, depending on genotypes at a specific locus, but it does not reveal whether the effect is dominant or recessive. To investigate this issue, all individuals were grouped by genotype at each of the SNPs showing significant correlation with CXCL13. For the HLA-DRB1*15 variant, the groups were assigned depending on the carriage of 0, 1 or two copies of the allele. Differences in CSF levels of CXCL13 between the different genotype groups were analyzed in Set 1 and Set 3, using the student's t-test with Welch's correction for unequal variances. We observed significant differences in CXCL13 levels in the group carrying one HLA-DRB1*15 allele, as well as in the group carrying two, when compared to groups carrying none (Figure 2(a) ). This indicated that there was a dominant effect of HLA-DRB1*15, where its presence was associated with higher CXCL13 levels in the CSF. The non-HLA risk alleles rs9321619-A 22 (OLIG3/TNFAIP3), rs4728142-A 17 (IRF5) and rs3807306-T 17 (IRF5) were significantly correlated with higher CXCL13 in a recessive manner (Figure 2(b-d) ). The group of subjects who were homozygous for the MS risk allele rs2760524-G 1 (RGS1) had significantly higher CXCL13 levels, when compared to the heterozygous group; but due to the very low minor allele frequency, the comparison between the two homozygous groups was not found to be statistically significant (Figure 2(e) ). Also, rs34925346 (RGMA), which has a very low MS risk allele (C) 20 frequency, resulted in a non-significant t-test, due to the low number of individuals and large spread of CXCL13 levels within the CC homozygous group. Therefore, it was not possible to draw any conclusions about the genotype effects associated with CXCL13 (Figure 2(f) ). The same significantly dominant or recessive effects were found in both Set 1 and Set 3 (but only Set 3 is shown in Figure 2 ).
We performed a bioinformatic scan for eQTLs that were regulating expression of CXCL13. None of the databases found the genetic markers reported here, nor any other marker in their proximity, as eQTLs for CXCL13 expression. Moreover, there are no reports of direct regulation of CXCL13 by any of the genes in closest proximity to these susceptibility loci. In an attempt to find any possible intermediate regulatory link between the correlated genotypes and the observed high CXCL13 levels, we measured mRNA expression of the proinflammatory cytokines IL6, TNF and IFN-γ in the CSF cells obtained from 390 of our study patients and in PBMCs from 369 of the study patients. The relative expression of each target gene was compared to the genotype at rs9321619 (OLIG3/TNFAIP3), rs4728142 (IRF5), rs3807306 (IRF5), rs2760524 (RGS1) and the presence of 0, 1 or 2 HLA-DRB1*15 alleles, as well as to CXCL13 protein levels. There was no significant difference found in gene expression between the different genotype groups analyzed, and there was no correlation found between IL6, TNF or IFN-γ gene expression in the CSF cells nor PBMCs, and the levels of CXCL13 protein in the CSF (data not shown).
Discussion
In this study, we found correlations between high mean levels of CXCL13 in the CSF and some of the genotypes that are associated with an increased risk of MS. These significant correlations were not present when the MS and CIS patients were not included in the analysis (see Table 1 , Set 2). Thus, our results suggested that the polymorphisms correlating with CXCL13 levels in CSF have a more pronounced effect in MS, and that the alleles associated with an increased risk for MS are also the ones that predispose to increased CXCL13 concentrations in CSF.
Because the functional impact of these CXCL13correlated polymorphisms is unknown, it is not possible to predict how transcription, translation, secretion and degradation of CXCL13 might be influenced by them; however, it may still be worthwhile to discuss the genes in which the polymorphisms are located.
HLA-DRB1 codes for the beta chain of the HLA class II molecules that are found on antigen presenting cells (APCs), such as B cells and dendritic cells. These molecules present antigens to T cells. The HLA-DRB1*15 allele is thought to be involved in the presentation of myelin antigens to autoreactive T cells, in MS. Previously, a correlation between a benign course of MS (defined as maintaining an EDSS score of < 3 for at least 10 years) and an absence of homozygotes for the HLA-DRB1*15associated haplotype (DR2) was described. 23 In another study, HLA-DRB1*15 positive patients were found to have higher intrathecal IgG synthesis levels, compared to HLA-DRB1*15 negative patients. In the same study, MMP-9, an enzyme that degrades the basement membrane during leukocyte migration across the blood-brain barrier and that is increased in active MS, was also found to correlate with HLA-DRB1*15 positivity. 24 These previous findings provide a suggestive link between CXCL13, a more severe disease course in MS and the carriage of HLA-DRB1*15. In a study published by Khademi et al., it was shown that CXCL13 levels were significantly increased in the oligoclonal immunoglobulin band (OCB)positive MS or CIS patients, as compared to OCB-negative MS or CIS. 7 Table 1 . Association of MS SNPs to CXCL13 mean levels in CSF.
CHR SNP RGS1 encodes a protein that belongs to the family of regulators of G-protein signaling, which terminate the signaling by accelerating GTP hydrolysis of activated GTP subunits. 25 It attenuates chemokine signaling through the G-protein coupled receptors CXCR4, and the CXCL13 receptor CXCR5, leading to a decreased B-cell migration. 26 RGS1 was found to be induced by IFN-β, both at the RNA and protein level, in human immune cells. 27 In our cohort, there were very few individuals who were homozygous for the protective A-allele; however, there was a highly significant difference in CXCL13 levels, between the heterozygotes and the homozygotes for the risk allele G, as is seen in Figure 2(e) ).
IRF5 is a transcription factor involved in Toll-like receptor-mediated proinflammatory responses. IRF5 transactivates genes such as IL6, TNF and type I interferons, by binding to the interferon-sensitive response elements (ISREs) in their promoters. 28 So far, IRF5 is reported to be associated with MS in Spanish, Finnish and Swedish populations, 17 as well as by Izaura Lima Bomfim et al., unpublished results; but this association has not been confirmed with genome-wide significance. It has recently been reported that patients who carry one of the IRF5 risk genotypes studied here, rs4728142-AA, are more likely to display a poor clinical response to IFN-β therapy. The response was measured by studying the expression differences of 10 IFN-induced genes. 29 rs4728142 is located ~5 kb upstream of the first exon of IRF5, and there seems to be a stronger binding of transcription factors to the risk allele A 17 , although to date, there were no conclusive studies performed regarding the possible impact on transcription factor binding nor any finding which possible transcription factors might bind to that site. The IRF5 gene has at least 13 splice variants (http://genome.ucsc.edu), some of which seem to be cell type-specific. 30 Whether rs3807306, located in the first intron, might have any influence on splicing remains to be investigated. Approximately 40 kb upstream of the CXCL13 gene, there is a predicted ISRE (http:// genome.ucsc.edu), yet not any studies reporting its possible regulatory influence on CXCL13.
The SNP rs9321619 is located in a region between two genes: OLIG3 and TNFAIP3. It has emerged as a strong susceptibility candidate SNP for MS, 22 and in the latest GWAS, that same region was confirmed genome-wide as significant; however, another SNP rs13192841 proved even more strongly associated (r 2 = 0.02 between rs9321619 and rs13192841). 1 This intergenic region is also associated with other inflammatory or autoimmune diseases, such as Crohn's and SLE. 31, 32 OLIG3 (Oligodendrocyte transcription factor 3) is a basic helix-loop-helix transcription factor with known involvement in the development of the nervous system. 33 TNFAIP3 functions as a negative regulator of nuclear factor-κB, a transcription factor that regulates the proinflammatory response of TNF. 34 Recent research shows that mice lacking the A20 (Tnfaip3) gene in dendritic cells develop systemic autoimmunity. 35 Because of its involvement in inflammation and autoimmunity, it is tempting to speculate that it is variability in the function of TNFAIP3, rather than in that of OLIG3, that affects disease susceptibility in autoimmune conditions.
In summary, since CXCL13 is associated with disease exacerbations and an unfavourable prognosis in MS, it is plausible that a certain genetic background is underlying such a phenotype. Our data provide an example of how a laboratory sub-phenotype of MS can become useful in dissecting gene variants associated with MS. This work encourages more and larger studies about the still-growing list of MS risk genes, as well as the search for any emerging biomarkers.
Some of the loci that we found here, especially RGS1 and IRF5, might point towards mechanisms that seem more directly involved in B-cell migration and response to IFN-β treatment, which in turn could be connected to the severity and progression of the disease. It is of note that CXCL13 is not a MS-specific marker, because it is elevated in other individuals with CNS infections, inflammatory states and autoimmune diseases; however, highly elevated levels, seen in combination with other protein or genetic markers such as carrying certain SNP genotypes, might help to indicate a worse prognosis or more severe disease, but this remains to be confirmed. Based on our results, replication of these studies in an independent patient group is warranted.
